The prevalence of chemical substance and alcohol abuse in an obstetric population in Dublin. by Bosio, P et al.
This article is a reproduction of that published in: Irish Medical Journal, 90(4), 1997, pp.149-150. Pagination may not 
match that of the original. 
 
The Prevalence of Chemical Substance and Alcohol Abuse in an 
Obstetric Population in Dublin 
P Bosio, *E Keenan, R Gleeson, *A Dorman, T Clarke, M Darling, *J O’Connor. 
Rotunda Hospital, Parnell Square, Dublin 1. *National Drug Advisory & Treatment Centre, Trinity Court, 31/32 
Pearse Street, Dublin 2. 
Abstract 
Objective: To determine the prevalence of illicit drug abuse and alcohol use in an obstetric 
population based in an urban maternity hospital. 
Setting: A collaborative study between the Rotunda Hospital, Dublin and the Irish National Drug 
Advisory & Treatment Centre. Design: A prospective study consisting of anonymous, unlinked 
urine testing of 504 ‘first visit’ antenatal patients and a separate group of 515 patients six weeks 
after delivery. 
Methods & Outcome Measures: Toxicological screening using enzyme-linked immunoassay 
techniques, with all positive samples being re-analysed. Drug histories were taken and samples 
were tested for alcohol and six of the most commonly abused drugs. The pre- and postnatal 
prevalence of abuse was matched with demographic data. 
Results: The prevalence of chemical substance misuse in the antenatal population was 2.8% and 
5.6% in the postnatal population. Substances identified included benzodiazepines, cannabis, 
amphetamines, opiates and cocaine. Less than 2% of samples tested positive for alcohol. None of 
the women yielding positive samples had been pre-identified on the basis of history. A significant 
proportion of the women were in the high risk categories with regard to age and socio-economic 
status  
Conclusion: The prevalence of drug misuse antenatally was nearly 3% and postnatally almost 6%. 
Substance abusers in pregnancy are more likely to be single, unemployed, and to have had a 
previous pregnancy. 
Introduction 
The prevalence of drug addiction in pregnancy is well documented in the USA1,3 but the 
magnitude of the problem in these islands remains unknown, although several retrospective 
studies have been conducted.4,6 Various maternal medical complications are associated with 
substance abuse, including neurologic, cardiovascular and respiratory conditions and an increased 
risk of infectious disease.7,9 Fetal and neonatal complications include: abortion, prematurity, 
intrauterine growth retardation, stillbirth, congenital malformation, abruptio placenta, fetal 
distress, neonatal toxicity and withdrawal syndrome and neurobehavioural abnormalities.10,14 
Frequently, the substance abuser lives in an environment where others use drugs and alcohol, and 
spousal or child abuse may occur in the home.” 
In the UK and Ireland the problem is allegedly much less common. However an accurate 
assessment of the prevalence of drug and/or alcohol misuse in pregnancy is necessary to allow a 
structured approach to resource allocation, intervention and follow-up. 
Subjects and Methods 
Anonymous, unlinked urine testing was performed on all women attending the Rotunda Hospital 
for their first antenatal visit over a six-week period as well as on a separate group of women 
attending for their six-week postnatal clinic. Over 1000 patients were screened for a 
comprehensive range of substances (Table 1). 
Midstream urine samples were collected by midwives and labelled with age, marital status, parity 
(including history of fetal loss), employment status and cigarette smoking. The samples were kept 
in cold storage and analysed within 48 hours. In addition, all patients were specifically questioned 
regarding their drug history, prescribed or otherwise, during the preceding four weeks. 
Toxicologic screening was performed using enzyme-linked immunoassay (EmitR d.a.u™ Assay) 
as a preliminary analytical test. The National Drug Advisory & Treatment Centre’s recommended 
cut-off levels were used to determine the presence of a drug or drug metabolite and all positive 
samples were re-analysed using gas chromatography to obtain a confirmed analytical result. This 
gave a negligible false positive rate. A positive test for alcohol was >10mg%. The screening 
results were then matched with the demographic data. The relationship between patient 
characteristics and urinalysis positivity was expressed as odds ratios. The confidence intervals for 
the odds ratios were calculated using an exact method algorithm implemented in the WHO/US 
CDC Software Statcalc.16 The Chi2 Test was used to compare antenatal versus postnatal 
prevalence of substance misuse. 
Table 1. Analysis of Substance Misuse in Antenatal and Postnatal Patients. 
Substance Antenatal (n=504) Postnatal (n=515) 
 No. % No. % 
Alcohol 7 1.4 
(average 30.3 mg%)
8 1.6 
(average 57.9 mg%) 
Cannabis 5 1.0 14 2.7 
Benzodiazepines 4 0.8 8 1.6 
Opiates 2 0.4 7 1.3 (1 codeine) 
Cocaine 1 0.2 - - 
Amphetamine 1 0.2 - - 
Methodone 1 0.2 - - 
Total Patients* 18 3.6% 36 7.0% 
* 3 antenatal patient with 2 substances & 1 postnatal patients with 2 substances. 
+ Excluding alcohol; Antenatal Prevalence -2.8% / Postnatal Prevalence - 5.6%. 
 
Results 
The results of the screening are shown in Table 1. A total of 504 antenatal and 515 postnatal 
patients were screened. Cannabis was the most common substance detected, its use being more 
prevalent postnatally. There were three patients who tested positive for two substances 
antenatally, i.e. cannabis and amphetamine, opiate and methadone and cannabis and alcohol. One 
postnatal patient tested positive for two substances (benzodiazepine and cannabis). A total of 
eighteen antenatal patients tested positive for one or more substances, giving a prevalence of 
3.6%. Excluding alcohol, the prevalence of substance misuse in this patient population was 2.8%. 
Table 2 matches the demographic characteristics of the test-positive and negative populations. 
Antenatally, the median age was the same in both groups. Almost 80% of the ‘positive’ group 
were single; nearly twice the rate of the ‘negative’ group. There was a high incidence of 
multiparous patients testing positive but the percentage of nulliparous women with a history of  
 
Table 2. Demographic Characteristics Antenatal/Postnatal Urinalysis. 
Factor Antenatal Patients Postnatal Patients 
 Positive Negative Positive Negative 
 (n=18) % (n=486) % (n=36) % (n=479) % 
Medium Age (Yrs) 27  27  26  28  
Marital Status         
Single 14 77.8 209 43.0 18 50.0 185 38.6 
         
Parity         
Primigravid 1 5.6 160 32.9 22 61.1 126 26.3 
Para 0 + Hx         
Fetal Loss 3 16.6 25 5.2 4 11.1 35 7.3 
Para ≥ 1 14 77.8 301 61.9 10 27.8 318 66.4 
Para ≥ + Hx         
Fetal Loss 5 27.8 61 12.6 2 5.6 43 9.0 
Hx Fetal Loss* 8 44.4 86 17.7 6 16.6 78 16.3 
Employment 
Status 
        
Unemployed 9 50.0 109 22.4 13 36.1 131 27.3 
Housewife 6 33.3 170 35.0 5 13.9 142 29.6 
         
Cigarettes 13 72.2 241 49.6 17 47.2 206 43.0 
* Regardless of parity 
 
Table 3. Positive Urinalysis and Patient Characteristics: Odds Ratios. 
Factor OR Antenatal 95% CI OR Postnatal 95% CI 
Single 4.6 1.4 to 19.6 1.6 0.8 to 3.3 
Primigravid 0.1 <0.01 to 0.8 4.4 2.0 to 7.4 
Para 0 Hx     
fetal loss 3.7 0.6 to 14 1.6 0.4 to 4.9 
Para ≥  2.1 0.7 to 9.1 0.2 0.08 to 0.4 
Para ≥ 1 + Hx     
fetal loss 2.7 0.7 to 8.3 0.6 0.07 to 2.5 
Hx fetal loss 2.3 0.7 to 6.9 1.0 0.3 to 2.6 
Unemployed 3.4 1.2 to 10.1 1.5 0.7 to 3.2 
Cigarettes 2.6 0.9 to 9.6 1.2 0.6 to 2.5 
fetal loss, either induced or spontaneous, was over three times that of the control group. The 
incidence of fetal loss amongst the positive urinalysis group, regardless of parity, was almost 
twice that of the control group. .50% of the women testing positive were unemployed versus 22% 
in the negative group. Expressing the relationship between positive urinalysis and patient 
characteristics as odds ratios shows that testing positive antenatally is predicted by being single, 
unemployed, and not being primigravid (Table 3). 
Postnatally, cannabis, benzodiazepine, opiate and alcohol use was more prevalent (p = 0.003). 
However no ‘hard drugs’ were found postnatally. The prevalence of substance misuse was 7.0% 
(5.6% excluding alcohol). There was little difference in median age between the test positive 
urinalysis group and the negative group. 50% of the postnatal ‘positive’ group were single, 35.7% 
were unemployed and 46.4% were cigarette smokers. All these figures were higher than in the 
relevant ‘negative’ group but the differences were not as marked as in the antenatal population. 
There was, however, a marked difference as regards parity; 61% of the positive urinalysis group 
were primigravidae versus 26% of the negative urinalysis group. There was no statistically 
significant difference between the positive and negative test groups as regards history of fetal 
loss. None of the test-positive patients admitted to having used either prescribed or illicit drugs 
within the preceding four weeks. 
Discussion 
A prevalence study based on urinalysis alone has some inherent limitations. Chemical use was 
ascertained from a single test linked to hospital attendance. Some patients who tested negative for 
drugs may have used cocaine, amphetamines or opiates at other times during pregnancy. Also, 
toxicologic studies of urine samples are limited in that a positive result reveals only that a 
particular substance has been used within a specified period of time before testing. That time 
interval is specific for the substance and is dependent on its metabolism and/or urinary excretion 
(ranging from one to two days for amphetamines, two to four days for opiates and cocaine and up 
to 30 to 70 days for some benzodiazepines or cannabinoids). Such tests therefore do not indicate 
the frequency of use or the amount used. Hence, the prevalence of alcohol and substance misuse 
is almost certainly under-reported in our data. 
Evidence of substance use was observed in 3.6% of our antenatal population and 7.0% of the 
postnatal population. Most of the published data based on prospective screening studies derives 
from the United States. Our prevalence figures are significantly lower than those reported from 
the USA where in 1989, a survey of 36 hospitals found that 11% of pregnant women had used an 
illegal drug at some point during the pregnancy.17 Zuckerman et al reported that 31% of women 
delivering in Boston City Hospital used marijuana and 18% used cocaine during pregnancy.2 
Chasnoff et al reported 14.8% of pregnant women had a positive urine toxicology screen for 
cocaine, marijuana, alcohol, or heroin.3 
Our results are similar to those published from Birmingham, England by Condie et al where 2% 
of women tested positive at the first visit antenatal clinic. That study failed to detect any cocaine 
metabolites or methadone.” Our study documented significant differences between the 
toxicology-positive and negative women, especially amongst the antenatal population. Women 
who tested positive antenatally were almost twice as likely to be single, unemployed and on a 
second or subsequent pregnancy. This close correlation with socio-economic deprivation has 
previously been well-documented.19 
Postnatally, the primigravid are more likely to test positive. Over 70% of the postnatal chemical-
positive women were first-time mothers possibly reflecting increased coping difficulties. None of 
our toxicology-positive patients (including the one patient on the methadone maintenance 
program), had been identified on the basis of history alone confirming previous suggestions that a 
drug history alone is not accurate for identifying chemical use among pregnant women.3,10 We 
used single urinalysis screening. Serial screening of high risk mothers during pregnancy would 
represent a more concerted effort to identify drug abusers. This may be financially beneficial 
since estimates of neonatal costs show that maternal treatment programs, where instituted early 
during pregnancy, are cost effective.20 However, excluding alcohol, possible occasional ‘medical’ 
drugs (opiates and benzodiazepines) and cannabis, all of which may be of little or no harm to 
mothers and babies, the prevalence of harmful drug misuse in the antenatal population was 0.6%. 
Notwithstanding-the limitations of single urinalysis screening, it would appear that drug abuse is 
not a serious problem among Dublin’s pregnant population. However, this does not take into 
account the fact that drug addicts are often unbooked patients presenting late or in labour or may 
attend elsewhere for termination of pregnancy. Unless larger studies yield a more significant 
prevalence, compulsory urinalysis for drugs of abuse would be difficult to justify. It would 
possibly also lead to substance misusing mothers avoiding treatment services at a time when they 
most need those services. 
There was a significantly lower prevalence of chemical substance and alcohol misuse during 
pregnancy when compared with the postnatal sample population. This is somewhat surprising in 
view of the fact that the postnatal sample, by virtue of voluntarily opting to return to the six-week 
clinic, is likely to be a more motivated and selective group. This may represent a more 
responsible pattern of behaviour during pregnancy with an increased effort to minimise exposure 
of the fetus to chemical substances. 
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